Effect of the 2013 asco-cap her2 testing guideline on the management of ihc/her2 2+ invasive breast cancer

MAI YAMADA, MAKOTO KUBO, HIDETAKA YAMAMOTO, Nami Yamashita, MASAYA KAI, KAREN ZAGUIRRE, KAZUHISA KANESHIRO, AKIKO SHIMAZAKI, SAORI HAYASHI, HITOMI KAWAJI, MASAKI MORI, YOSHINAO ODA, MASAFUMI NAKAMURA

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: With advances in anti-HER2 treatment and improved prognoses of HER2-positive breast cancer, the American Society of Clinical Oncology and the American Society of Pathologists (ASCO/CAP) have revised the HER2 diagnostic guidelines several times. We examined how to respond clinically to the revisions of the interpretation of the immunohistochemistry (IHC) method. Patients and Methods: We re-evaluated 254 patients diagnosed as HER2 IHC equivocal, who underwent fluorescence in situ hybridization (FISH) before and after the IHC diagnostic criteria update in 2013. Results: Twenty of 131 (15.3%) IHC equivocal cases by the ASCO/CAP 2007 guideline were IHC score 3+ and one of 20 (0.76%) was negative for FISH. Five of 123 (4.1%) IHC equivocal cases by the ASCO/CAP 2013 guideline were negative for IHC as per the 2007 guideline and four were positive for FISH. Conclusion: After revision of the ASCO/CAP 2013 guideline, 3.3% of HER2-negative cases before the revision should have received anti-HER2 treatment.

Original languageEnglish
Pages (from-to)4143-4149
Number of pages7
JournalAnticancer research
Volume41
Issue number8
DOIs
Publication statusPublished - Aug 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Effect of the 2013 asco-cap her2 testing guideline on the management of ihc/her2 2+ invasive breast cancer'. Together they form a unique fingerprint.

Cite this